Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 117-126

  Warnke, Clemens ^a   Wiendl, Heinz ^b   Hartung, Hans Peter ^a   Stüve, Olaf ^c   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Immunosuppressant; Oral drugs; Risk benefit; Safety

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; PLACEBO; DRUG DERIVATIVE; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADD ON THERAPY; BONE MARROW SUPPRESSION; CHORIOCARCINOMA; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HERPES ZOSTER; HERPES ZOSTER OTICUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PANCREAS CARCINOMA; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENICITY; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA IN SITU; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; CLADRIBINE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 79952033985     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449-1463.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
3. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4): 662-667.
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet. 1998;352(9139): 1498-1504.
5. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628-1636.
6. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferonbeta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by Interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol. 1999;46(2):197-206.
7. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry. 1999;67(4):451-456.
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-1276.
9. Comi G, Filipi M, Wolinsky JS; For the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001; 49:290-297.
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
11. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1998;43:79-87.
12. Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2009; 10:291-309.
13. Perumal J, Filippi M, Ford C, et al. Glatiramer acetate therapy for multiple sclerosis: a review. Expert Opin Drug Metab Toxicol. 2006; 2:1019-1029.
14. Francis G. Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis. Expert Opin Drug Saf. 2004;3:289-303
15. Durelli L, Verdun E, Barbero P, et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453-1460.
16. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, openlabel trial. Lancet Neurol. 2008;7(10):903-914.
17. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-1983.
18. O'Connor P, Filippi M, Arnason B, et al. 250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-897.
19. Barbero P, Bergui M, Versino E, et al. INCOMIN Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler. 2006;12: 72-76
20. Schwid SR, Thorpe J, Sharief M, et al. EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol. 2005;62:785-792.
21. Panitch H, Goodin DS, Francis G, et al. EVIDENCE Study Group. EVidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59:1496-1506.
22. Panitch H, Goodin D, Francis G, et al. EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/ MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comarative results of the EVIDENCE trial. J Neurol Sci. 2005;239:67-74.
23. Lublin FD. When marketing and science intersect: do patients with MS benefit? Neurology. 2002;59:1480-1481.
24. Kieburtz K, McDermott M. Needed in MS: Evidence, not EVIDENCE.Neurology. 2002;59:1482-1483.
25. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract. 2007;61:1922-1930.
26. Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11:306-309.
27. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing- remitting multiple sclerosis. J Neurosci Nurs. 2006;38: 167-171
28. Cohen BA. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care. 2006; Suppl:32-37.
29. Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand. 2006; 113:156-162.
30. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551-554
31. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007; 56(25):2622-2629.
32. Rice GPA, Hartung H, Calabresi PA. Anti-alpha4 integrin therapy for ultiple sclerosis: mechanisms and rationale. Neurology. 2005;64(8): 336-1342.
33. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled rial of natalizumab for relapsing multiple sclerosis. N Engl Med. 2006;354(9):899-910.
34. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon eta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9): 11-923.
35. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal eukoencephalopathy complicating treatment with natalizumab and nterferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4): 69-374
36. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. rogressive ultifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381
37. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal eukoencephalopathy after natalizumab therapy for Crohn's disease.N Engl J Med. 2005;353(4):362-368
38. Hartung H. New cases of progressive multifocal leukoencephalopathy fter treatment with natalizumab. Lancet Neurol. 2009;8(1):28-31.
39. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal eukoencephalopathy after natalizumab monotherapy. N Engl J Med. 009;361:1081-1087.
40. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009;361:1075-1080
41. Molloy ES, Calabrese LH. Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol. 2009;5(8):418-419.
42. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113:4834-4840.
43. Coles AJ, Compston DAS, Selmaj KW, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17): 1786-1801.
44. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs. 2007;21(6):483-502
45. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
46. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5): 416-426.
47. Kappos L, Radue E, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401
48. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5): 402-415.
49. Carroll WM. Oral therapy for multiple sclerosis - sea change or incremental step? N Engl J Med. 2010;362(5):456-458.
50. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2 chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737-743.
51. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74:5677-5681.
52. Sipe JC. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Rev Neurother. 2010; 10(3):365-375.
53. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32:120-131.
54. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 50-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81:597-601.
55. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989;49:6923-6928.
56. Rieckmann P, Comi G, Cook S, et al. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96 week, Phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Duesseldorf, Germany, 2009 Sep 9-12. Mult Scler. 2009;15:S248-S249.
57. Salvat C, Curchod ML, Guedj E, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis. Procedings and Abstracts of the Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dusseldorf, Germany, 2009 Sep 9-12 (Poster presentation P280).
58. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54:1145-1155.
59. Hartung H, Aktas O, Kieseier B, Giancarlo Comi GC. Development of oral cladribine for the treatment of multiple sclerosis. J Neurol. 2010; 257(2):163-170.
60. Soelberg-Sorensen P, Comi G, Cook S, et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double-blind, placebo-ontrolled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, 2009 Sep 9-12. Mult Scler. 2009;15:S137.
61. Kopadze T, Dobert M, Leussink VI, Dehmel T, Kieseier BC. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol. 2009;16:409-412.
62. Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, Belniak E. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand. 2010. [Epub ahead of print].
63. Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit. 2001;7:93-98.
64. Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand. 2004;109:390-392.
65. Laugel B, Challier J, Siegfried C, Chvatchko Y, Weissert R, Galibert L. Cladribine exerts a modulatory effect of T cell activation. Mult Scler. 2008;14:S52-S53.
66. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol. 1996;14:2160-2166.
67. Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol. 2004;80:267-277
68. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med. 1994;120:784-791.
69. Schirmer M, Mur E, Pfeiffer KP, Thaler J, Konwalinka G. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol. 1997;26:376-379.
70. Davis JC Jr, Austin H III, Boumpas D, et al. A pilot study of 2-chloro-20-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum. 1998;41:335-343.
71. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996;93:1716-1720.
72. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111:35-44.
73. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin. 2007;23:2667-2676.
74. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
75. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33: 1444-1452.
76. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-846.
77. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17:2454-2460.
78. Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997;15:1803-1810.
79. Cook S. A combined analysis of data from four randomized, double-blind, placebo-control led trials of parenteral cladribine andone open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis (P02.180). Neurology (American Academy of Neurology Meeting, Chicago 2008).
80. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140.
81. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology.2006;66(6):894-900.
82. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64(6):987-991.
83. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-1472.